Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

BACKGROUND: To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC). METHODS: 154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karthaus, Meinolf, Hofheinz, Ralf-Dieter, Mineur, Laurent, Letocha, Henry, Greil, Richard, Thaler, Josef, Fernebro, Eva, Oliner, Kelly S, Boedigheimer, Michael, Twomey, Brian, Zhang, Ying, Demonty, Gaston, Köhne, Claus-Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104899/
https://www.ncbi.nlm.nih.gov/pubmed/27764839
http://dx.doi.org/10.1038/bjc.2016.343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104899/
https://www.ncbi.nlm.nih.gov/pubmed/27764839
http://dx.doi.org/10.1038/bjc.2016.343

Ejemplares similares